Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL146034 | 0.84 | IDO1 (0.45) | SMN1; SMN2ALDH1A1TSHRHSD17B10ALOX15 | |
| SCHEMBL22548827 | 0.78 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL13624227 | 0.77 | CA1 (0.42) | SMN1; SMN2NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL14081010 | 0.76 | KMT2A (0.42) | SMN1; SMN2NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL25095026 | 0.76 | TSHR (0.40) | SMN1; SMN2ALDH1A1TSHRHSD17B10ALOX15 | |
| SCHEMBL7794063 | 0.76 | MAPT (0.58) | SMN1; SMN2NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL222689 | 0.76 | ALDH1A1 (0.52) | SMN1; SMN2NPC1RAB9AKMT2AALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL6698868 | 0.74 | MAPT (0.56) | SMN1; SMN2NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL14081111 | 0.74 | IDO1 (0.43) | SMN1; SMN2KMT2AALDH1A1CA1CA2 | |
| SCHEMBL1800738 | 0.74 | MEN1 (0.44) | SMN1; SMN2NPC1RAB9AKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752617-B2 | Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-08-25 | — | — | US | disclosed |
| US-20190202819-A1 | INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-07-04 | — | — | US | disclosed |
| US-10246440-B2 | Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR γ (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-04-02 | — | — | US | disclosed |
| US-20170342062-A1 | INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-11-30 | — | — | US | disclosed |
| EP-3233836-A1 | INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | Galderma Research & Development (FR) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016097391-A1 | INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246440-B2 | Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR γ (T)) | RORA, RORB, RORC | SMN1; SMN2 4630/4885NPC1 983/4885RAB9A 2294/4885 |
| US-20170342062-A1 | INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | RORA, RORB, RORC | SMN1; SMN2 4627/4885NPC1 1049/4885RAB9A 2290/4885 |
| US-20190202819-A1 | INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) | RORA, RORB, RORC | SMN1; SMN2 4627/4885NPC1 1049/4885RAB9A 2290/4885 |
| US-10752617-B2 | Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T)) | RORA, RORB, RORC | SMN1; SMN2 4627/4885NPC1 1049/4885RAB9A 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.